➤ 2021 ASCRS Annual Meeting update ➤ FDA approves new monofocal IOL ➤ First patient dosed in Phase 2 trial for investigational DED therapy ➤ Phase 2a trial initiated for add-on wet AMD therapy
➤ Topline results from Phase 3 studies for nAMD treatment ➤ Phase 2 trial of betamethasone treatment for cataract surgery pain and inflammation ➤ Fast Track designation given to therapy seeking to treat achromatopsia ➤ Topline data from Phase 1 trial of travoprost intracameral implant ➤ ASCRS Journal Club
➤ Enrollment complete for Phase 3 studies of investigational dry eye drug ➤ Update from two Glaukos trials ➤ Study: Remote monitoring with implantable IOP sensor affects clinical decision making ➤ ASCRS events
➤ Commercial launch of Alcon’s Vivity IOL ➤ Topline results from Phase 2 trial for treatment of contact lens discomfort ➤ Company registers new artificial intelligence visual field exam device with FDA ➤ Positive Phase 3 results for faricimab for DME ➤ Research begins to create a MIGS patient-reported outcomes instrument ➤ ASCRS events
“In the day and age of refractive cataract surgery, optimizing outcomes is extremely important,” said Kathryn Hatch, MD, as she introduced a webinar hosted by the ASCRS Refractive Surgery Clinical Committee earlier this year. “We have increasing patient expectations, and it’s extremely important that we obtain ideal biometry measurements. To do so, we need to pay specific attention to the ocular surface, especially when treating astigmatism and presbyopia.”